2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
2014/09/27 by Désirée van der Heijde, Daniel Aletaha, Loreto Carmona +8 · 38 citations
Economics, Econometrics and Finance · Medicine · #Health Systems, Economic Evaluations, Quality of Life #Musculoskeletal Disorders and Rehabilitation #Rheumatoid Arthritis Research and Therapies
paper · pdf · doi:10.1136/annrheumdis-2014-206350
Abstract
In this article, the European League Against Rheumatism (EULAR) standardised operating procedures for the elaboration, evaluation, dissemination and implementation of recommendations endorsed by the EULAR standing committees published in 2004 have been updated. The various steps from the application to implementation have been described in detail.
Cited by
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
- EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- EULAR recommendations for the management of antiphospholipid syndrome in adults
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
- 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
- Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
- Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement
- EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. [europepmc]
- Consensus-based recommendations for the management of juvenile dermatomyositis. [europepmc]
- Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. [europepmc]
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. [europepmc]
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. [europepmc]
- Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis. [europepmc]
- EULAR recommendations for the management of antiphospholipid syndrome in adults. [europepmc]
- EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. [europepmc]
- Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. [europepmc]
- Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. [europepmc]
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. [europepmc]
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. [europepmc]
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. [europepmc]
- Digital rheumatology in the era of COVID-19: results of a national patient and physician survey. [europepmc]
- 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. [europepmc]
- EULAR recommendations for intra-articular therapies. [europepmc]
- EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. [europepmc]
- EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. [europepmc]
- The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. [europepmc]
- Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. [europepmc]
- Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. [europepmc]
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. [europepmc]
- The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). [europepmc]
- EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. [europepmc]
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. [europepmc]
Related